Lecap Asset Management Ltd. Purchases Shares of 4,770 Illumina, Inc. $ILMN

Lecap Asset Management Ltd. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,770 shares of the life sciences company’s stock, valued at approximately $626,000.

Other hedge funds have also bought and sold shares of the company. Symmetry Partners LLC bought a new position in Illumina during the fourth quarter worth about $230,000. Asset Management One Co. Ltd. lifted its position in shares of Illumina by 10.3% in the fourth quarter. Asset Management One Co. Ltd. now owns 125,230 shares of the life sciences company’s stock valued at $16,837,000 after buying an additional 11,679 shares during the last quarter. Werba Rubin Papier Wealth Management bought a new position in shares of Illumina during the 4th quarter worth approximately $226,000. Merit Financial Group LLC increased its holdings in shares of Illumina by 27.3% during the 4th quarter. Merit Financial Group LLC now owns 23,834 shares of the life sciences company’s stock worth $3,126,000 after acquiring an additional 5,113 shares during the last quarter. Finally, AE Wealth Management LLC raised its stake in Illumina by 5.4% in the 4th quarter. AE Wealth Management LLC now owns 22,499 shares of the life sciences company’s stock valued at $2,951,000 after acquiring an additional 1,162 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

ILMN opened at $134.50 on Monday. The stock has a fifty day moving average of $123.81 and a 200-day moving average of $124.95. The company has a market capitalization of $20.43 billion, a P/E ratio of 24.68, a P/E/G ratio of 2.58 and a beta of 1.49. Illumina, Inc. has a fifty-two week low of $69.83 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the prior year, the company posted $0.95 earnings per share. Illumina’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on ILMN. Piper Sandler reduced their price objective on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a report on Monday, January 26th. UBS Group restated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Finally, Stifel Nicolaus boosted their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Six equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $129.69.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.17% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.